



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Palynziq

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Form with fields: Patient Name, Prescriber Name, HPP Member Number, Date of Birth, Patient Primary Phone, Address, City, State ZIP, Line of Business, Drug Name, Quantity, Directions, Diagnosis Code, Diagnosis, etc.

HPP's maximum approval time is 12 months but may be less depending on the drug.

Please attach any pertinent medical history including labs and information for this member that may support approval.

Please answer the following questions and sign.

Q1. Is this a renewal?
Q2. Is the patient 18 years of age or older?
Q3. Is Palynziq being prescribed by or in consultation with a metabolic diseases specialist or a provider who specializes in the treatment of PKU?
Q4. Does the patient have a diagnosis of uncontrolled phenylketonuria confirmed by baseline blood phenylalanine concentrations greater than 600 micromol/L?
Q5. Has the patient tried non-pharmacological treatment options (such as restriction of dietary phenylalanine intake)?
Q6. Does the patient have a documented trial and failure of or contraindication/intolerance to Kuvan (Kuvan will require Prior Authorization)?

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party.



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Palynziq

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q7. Are both the patient and prescriber enrolled in The Palynziq REMS Program?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q8. Has auto-injectable epinephrine been prescribed and has the patient been instructed on proper use and to have it on them at all times? Chart notes documenting that auto-injector epinephrine has been prescribed to the patient and counseling has been done must be attached.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q9. Is there documentation that the initial dose will be administered under the supervision of a healthcare provider?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q10. Is there documentation showing Palynziq will be initiated at the recommended induction dose?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q11. Is there documentation showing Palynziq will be titrated over at least 5 weeks after completing the 4-week induction period?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q12. Is there documentation showing that the Palynziq dose will be maintained at 20 mg subcutaneously once daily for at least 24 weeks?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q13. Is there documentation that Palynziq will not be used in combination with sapropterin dihydrochloride (if applicable)?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q14. Has the patient been approved for treatment with Palynziq previously?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q15. Has the patient experienced any serious side effects (such as anaphylactic events) while being treated with Palynziq?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q16. Has the patient been compliant with filling their prescription?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q17. Is there documentation that the patient is stable on their current dose of Palynziq? Including documentation showing a blood phenylalanine concentration less than or equal to 600 micromol/L? Labs must be attached.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



HEALTH PARTNERS PLANS
PRIOR AUTHORIZATION REQUEST FORM

Health Partners Plans

Palynziq

Phone: 215-991-4300

Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:
---------------	------------------

<p>Q18. Is there documentation showing the patient has not achieved a blood phenylalanine concentration less than or equal to 600 micromol/L after 24 weeks of continuous treatment with 20 mg subcutaneously once daily? Labs must be attached.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q19. Is there a titration plan in place showing that the patient's dosage will be increased to 40 mg subcutaneously once daily for at least 16 weeks?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q20. Is there documentation showing the patient has not achieved a blood phenylalanine concentration less than or equal to 600 micromol/L after 16 weeks of continuous treatment with 40 mg subcutaneously once daily? Labs must be attached.</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q21. Is there documentation showing the patient's dosage will be increased to a maximum of 60 mg subcutaneously once daily for at least 16 weeks?</p> <p><input type="checkbox"/> Yes <input type="checkbox"/> No</p>
<p>Q22. Requested Duration:</p> <p><input type="checkbox"/> 4 months <input type="checkbox"/> 8 months</p>
<p>Q23. Additional Information:</p>

Prescriber Signature

Date

Updated for 2022